Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Caribou Biosciences announces positive CRISPR hybrid RNA-DNA data

The company's stock ticked up after revealing the data. 

By Brian Buntz | September 3, 2021

Caribou BiosciencesCaribou Biosciences (NSDQ:CRBU) has announced the publication of data showing that its CRISPR hybrid RNA-DNA (chRDNA) guide technology supports better CRISPR associated protein 9 (Cas9) specificity compared with all-RNA guides. The Berkeley, California–based company’s technology thus enabled accuracy in intended genomic edits in cells while minimizing off-target events. 

High Cas9 specificity is useful in the development of therapeutics. 

In an article in Molecular Cell, report authors concluded that the findings “pave the way for utilizing customized chRDNAs in clinical applications.”

Steven Kanner

Steve Kanner

Caribou is developing allogeneic CAR-T cell therapies with multiple genome edits as potential therapies for hematologic malignancies. “By altering the position and number of DNA residues in our chRDNA guides, we readily achieve optimal on-target editing and minimize unintended off-target edits that may be problematic in therapeutic applications,” said Steve Kanner, Caribou’s chief scientific officer, in a statement.

In separate news, the company announced that it had dosed the first patient in the ANTLER Phase 1 clinical study focused on CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma. The company expects data from that trial in 2022. 

The company is also partnering with AbbVie (NYSE:ABBV) on two allogeneic CAR-T programs and has three proprietary allogeneic cell therapy candidates in development. 

CRBU shares ticked up 2.19% apiece to $29.12 in Friday afternoon trading. 

Earlier this year, Caribou raised $304 million earlier this year via an initial public offering.

More recently, it added a new member to its board of directors.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: CAR-T cell therapies, Caribou Biosciences, Cas9, chRDNA, CRISPR associated protein 9, CRISPR hybrid RNA-DNA
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50